Clinical Trials Logo

Mastitis clinical trials

View clinical trials related to Mastitis.

Filter by:

NCT ID: NCT06317688 Enrolling by invitation - Breast Feeding Clinical Trials

Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis

Start date: November 6, 2023
Phase: Phase 1
Study type: Interventional

Problem of the Study This study was designed to test the effectiveness of the application of extra-virgin coconut oil versus Highly Purified Anhydrous (HPA) Lanolin in ameliorating nipple pain, cracking and eventually the prevention of subacute lactation mastitis in breastfeeding women. It is theorized that the nipple crack, nipple pain are early warning signs of subacute clinical lactation mastitis. Goal is after application of extra-virgin coconut oil comparative analysis will be done at one week, three weeks, and six weeks. These complications associated with development of subacute mastitis can be addressed early during the first six weeks of lactation.

NCT ID: NCT05974956 Completed - Mastitis Clinical Trials

Effect of a Nursing Teaching Protocol on Mastitis Prognosis: Quasi-Experimental Research Design

Mastitis
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Aim: Evaluate the effect of a nursing teaching protocol on mastitis prognosis. Research design: Quasi-experimental research design was utilized. A convenient sample of sixty adult female patients diagnosed with mastitis, Patients divided equally into two groups(study and control) thirty for each.

NCT ID: NCT05852171 Recruiting - Clinical trials for Idiopathic Granulomatous Mastitis

Baricitinib in Idiopathic Granulomatous Mastitis

Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

This study will explore the mechanism of targeted drug in treatment of idiopathic granulomatous mastitis, and clarify the clinical classification and corresponding markers.

NCT ID: NCT05794945 Recruiting - Mastitis Postpartum Clinical Trials

Optimizing Mastitis Identification and Treatment

OPTIMIST
Start date: October 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to gain more information about the aetiology and progression of mastitis and breast inflammation, in order to develop evidence-based clinical guidelines and treatment plans, especially concerning judicious use of antibiotics. The main questions it aims to answer are: - Do clinical symptoms differ between inflammatory and infectious mastitis? - What is the microbial composition in human milk, and does it change before, during, and after episodes of mastitis? - Does the bacterial composition change due to antibiotic treatment? - Are all mastitis episodes treated with antibiotics bacterial mastitis? - Do mothers with recurrent mastitis have a distinct microbial composition? - Are there immunological markers that can differentiate between bacterial and inflammatory mastitis? Researchers will compare breastfeeding women with and without mastitis to see if the microbiological composition in milk and on the skin of the breast and breast nipple differs.

NCT ID: NCT05762016 Active, not recruiting - Breast Infection Clinical Trials

Outcomes of a Novel Technique of Mini- Incision and Self-Express (MISE) for Breast Abscess

Start date: January 1, 2018
Phase:
Study type: Observational

Conventional techniques for treatment of breast abscess, such as incision and drainage/percutaneous drainage, have disadvantages. Bedside Mini-Incision and Self-Express (MISE) is a novel technique for breast abscess. The outcomes of MISE were compared to the conventional techniques.

NCT ID: NCT05530226 Recruiting - Clinical trials for Plasma Cell Mastitis

A Single Arm Study of Traditional Chinese Medicine for Plasma Cell Mastitis

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

This is a single-center, single-arm, open-label trial evaluating the efficacy and safety of traditional Chinese medicine for plasma cell mastitis.

NCT ID: NCT05409586 Completed - Clinical trials for Idiopathic Granulomatous Mastitis

Risk Factors and the Role of Albumin-to-globulin Ratio in Idiopathic Granulomatous Mastitis

Start date: April 20, 2022
Phase:
Study type: Observational

Albumin-to-globulin ratio (AGR) is an inflammation-based index that has been shown to have a role in many cancers and inflammatory diseases. Idiopathic granulomatous mastitis (IGM) is a rare inflammatory disease of the breast with a high recurrence rate. As a relatively new biomarker for inflammatory diseases, AGR's role in IGM recurrence has never been investigated in the literature. This study primarily investigates the possible risk factors for IGM recurrence and whether AGR can be used as a predictive factor.

NCT ID: NCT05395949 Enrolling by invitation - Clinical trials for Psychiatric Disorder

A Randomized Controlled Study of Conservative Treatment of Granulomatous Lobular Mastitis Combined With Psychiatric Disorders

GLMwPD
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Granulomatous lobular mastitis (GLM) is a relatively rare chronic inflammatory disease of the breast in clinical practice. A small number of patients develop hyperprolactinemia during psychiatric drug treatment, and most of these patients are nulliparous. At present, there is no unified treatment mode at home and abroad, and surgery is generally the main treatment. GLM is a sterile inflammation, and glucocorticoids and methotrexate can effectively relieve clinical symptoms and even reach the standard of cure. In order to reduce the recurrence rate and protect the breast appearance as much as possible, we propose a conservative therapy. The purpose of this study was to compare this conservative therapy of granulomatous lobular mastitis with existing surgical treatment, and to compare the overall benefits of the two for patients with GLM. We aim to protect the breast appearance on the premise of low recurrence, improve the quality of life of GLM patients with psychiatric disorders .

NCT ID: NCT05361629 Recruiting - Clinical trials for Idiopathic Granulomatous Mastitis

Idiopathic Granulomatous Mastitis Combination Therapy

IGM-COMBO
Start date: April 16, 2022
Phase: N/A
Study type: Interventional

After breast cancer, diopathic Granulomatous Mastitis (IGM) is among the breast diseases that bother patients and clinicians the most. Countries with a coast to the Mediterranean, especially our country, are the most common geography of this disease. For this reason, a significant part of the important scientific publications about IGM in the last 3-4 decades are from the countries of this geography and mainly from our country. The paradigm of whether IGM should be treated medically or surgically is still a matter of debate. Today, effective treatment results can be achieved with medical treatments, and local drug applications are finding an increasing application area in order to reduce the systemic drug level due to the side effects often seen in this process. As in the centers dealing with breast diseases intensively in our country, patients are treated in our center both by systemic and local means. Within the body of the Turkish Breast Diseases Federation, after the plans made with the employees of the leading breast centers of the International Breast Health Working Group International planned to start a recording study to observe the activity between, local treatment in the lesion without surgical treatment with systemic treatment in IGM treatment and local treatment together with surgical treatment.

NCT ID: NCT05281419 Recruiting - Clinical trials for Refractory Granulomatous Lobular Mastitis

Combined Intralesional Triamcinolone Injection With Whole Breast Detection Radical Surgery

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Granulomatous lobular mastitis (GLM) is a rare, chronic benign inflammatory disease of the breast, of unknown etiology. Pathologically, GLM typically manifests as non-caseating granulomatous lesions with leukomonocytes, lymphocytes, neutrophils and multinucleated giant cells, located in the center of breast lobules. With a rapidly increasing morbidity in the last two decades, GLM tends to occur in child-bearing women with a prolonged and recurrent course. Intralesional injection and topical corticosteroids can effectively reduce the side effects, especially in patients suffering from concomitant skin lesions (e.g., fistula, skin erosions, ulcers).For patients with diffuse disease, recurrence, or ineffective conservative treatment, wide local excision can be applied.